Company intelligence / Profile preview

StromaCare

Lyon, Auvergne-Rhône-Alpes, Francestroma.care ↗

Ownership: Private
Development stage: Other

Overview

StromaCare is advancing its lead product, a monoclonal antibody therapy targeting the tumor stroma, toward First-in-Human clinical trials for multiple solid cancers. The company focuses on modulating stromal components to inhibit tumor growth, immune escape, and metastasis while enhancing drug delivery and surgical outcomes. No published clinical results yet; programs are in preclinical or early translational stages.

Therapeutic areas: Oncology
Modalities: Monoclonal antibodyBiologic (inferred from monoclonal antibody development)
Industry: Biotech

Drug pipeline

1 asset

STRO-501

Unknown

Partnerships

No major pharmaceutical or biotech partnerships have been publicly disclosed.

Beyond the preview

Go deeper on StromaCare.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on StromaCare.

Explore the full profile